Revenue isn’t expected until 2020.....but here’s
Revenue isn’t expected until 2020.....but here’s how:
1) combo approval
2) sell leronlimab
Per independent study, combo market is 49,000 people (49,000 is based on extreme conservative numbers.....but full year). At $70,000 price point this is a little over 7,000 people (current price for R3 drug that has less efficacy and worse SAEs is $118,000/year).
They also have prostate prognostic test that has potential of up to $750,000,000 annual revenue. This is based on 250,000 test done annually at low end of current test at $3,000. This test is 5-8 times more accurate than any currently on the market.
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Innovative Green Technologies from Shanghai Electric Transform Energy Landscape Shanghai Electric has remarkable aspirations for a sustainable and cleaner future. At a recent summit, the company proudly showcased its pioneering technologies geared towards green energy, including advancements in green hydrogen, sustainable formaldehyde production, photovoltaics,...
Continue Reading
Northview Residential REIT Announces Cash Distribution CALGARY, Alberta — Today, Northview Residential REIT, often recognized for its focus on quality real estate investments, made an important announcement regarding its August 2025 cash distribution amounts. This announcement showcases the REIT’s ongoing commitment to providing value to its investors. Details of the...
Continue Reading
Virpax Pharmaceuticals Experiences Remarkable Growth Virpax Pharmaceuticals, Inc. recently made headlines as their stock witnessed an impressive surge. This excitement primarily stems from the successful conclusion of a preclinical study that the U.S. Army's Institute of Surgical Research conducted. The study was part of a larger effort aimed at enhancing pain management...
Continue Reading
Boomi recognized for building an innovative workplace Boomi™, the intelligent integration and automation leader, was named to Fast Company’s annual Best Workplaces for Innovators list. The honor underscores Boomi’s focus on creating a place where new ideas move freely, teams experiment, and that open exchange shows up in how customers are supported every day. How...
Continue Reading
Faruqi & Faruqi, LLP Launches Investigation for Marex Group Investors Investors who have faced difficulties due to their investments in Marex Group plc are encouraged to reach out to Faruqi & Faruqi, LLP. The leading national securities law firm specializing in protecting investors' rights has begun a new investigation aimed at determining the merits of claims against the...
Continue Reading
